Humulin R
Hepatitis C Virus
McGill University Health Centre/Research Institute of the McGill University Health CentreN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hepatitis C Virus cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PARITAPREVIR AbbVie | Phase 4 | A |
Dasabuvir AbbVie | Phase 3 | A |
OMBITASVIR AbbVie | Phase 3 | A |
RITONAVIR AbbVie | Phase 3 | BBB |
COLCHICINUM Beth Israel Deaconess Medical Center | Phase 4 | BB |
Peg-Intron Beth Israel Deaconess Medical Center | Phase 4 | BB |
Pegylated-Interferon-Lambda Bristol-Myers Squibb | Phase 3 | BB |
Same molecule, other indications
Humulin R is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →